Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 October 2006Website:
http://www.sonnetbio.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:54:30 GMTDividend
Analysts recommendations
Institutional Ownership
SONN Latest News
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq®) will be presented as a ‘Trial in Progress' poster at ASCO 2024. Study SB221 (NCT05756907) is a Phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered SC, either alone or in combination with a fixed dose of atezolizumab given IV. The work will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2024, to be held May 31 to June 4 in Chicago, Illinois.
Sonnet BioTherapeutics (NASDAQ: SONN ) stock is falling on Wednesday after the biotechnology company revealed details of a public share offering. That public stock offering has Sonnet BioTherapeutics selling 2,843,750 shares of SONN stock at a price of $1.60 each.
Sonnet BioTherapeutics (NASDAQ: SONN ) stock is taking a beating on Monday after the company announced a public stock offering. Investors will note that this public stock offering comes from selling stockholders and not directly from Sonnet BioTherapeutics.
PRINCETON, NJ / ACCESSWIRE / April 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) on Tuesday, April 18, 2023 at 5:00 pm ET. Webcast presenters will include: Richard Kenney, M.D.
What type of business is Sonnet BioTherapeutics Holdings?
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
What sector is Sonnet BioTherapeutics Holdings in?
Sonnet BioTherapeutics Holdings is in the Healthcare sector
What industry is Sonnet BioTherapeutics Holdings in?
Sonnet BioTherapeutics Holdings is in the Biotechnology industry
What country is Sonnet BioTherapeutics Holdings from?
Sonnet BioTherapeutics Holdings is headquartered in United States
When did Sonnet BioTherapeutics Holdings go public?
Sonnet BioTherapeutics Holdings initial public offering (IPO) was on 31 October 2006
What is Sonnet BioTherapeutics Holdings website?
https://www.sonnetbio.com
Is Sonnet BioTherapeutics Holdings in the S&P 500?
No, Sonnet BioTherapeutics Holdings is not included in the S&P 500 index
Is Sonnet BioTherapeutics Holdings in the NASDAQ 100?
No, Sonnet BioTherapeutics Holdings is not included in the NASDAQ 100 index
Is Sonnet BioTherapeutics Holdings in the Dow Jones?
No, Sonnet BioTherapeutics Holdings is not included in the Dow Jones index
When does Sonnet BioTherapeutics Holdings report earnings?
The next expected earnings date for Sonnet BioTherapeutics Holdings is 14 August 2024